Showing results (1-10 of 470) with videos related to
Sort By:
Pageof 47
Nature Reviews. Clinical Oncology|December 24, 2014
Developing biomarker-specific end points in lung cancer clinical trialsJoel W Neal, Justin F Gainor, Alice T ShawThe Oncologist|July 2, 2013
Novel targets in non-small cell lung cancer: ROS1 and RET fusionsJustin F Gainor, Alice T ShawJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancerJustin F Gainor, Alice T ShawCancer Discovery|June 11, 2013
The new kid on the block: RET in lung cancerJustin F Gainor, Alice T ShawClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancerJoel W Neal, Alice T ShawJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancerJustin F Gainor, Sai-Hong Ignatius Ou, Jennifer Logan, et al.JTO Clinical and Research Reports|September 30, 2021
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLCJustin F Gainor, Shirish Gadgeel, Sai-Hong I Ou, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2017
A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain MetastasisIbiayi Dagogo-Jack, Michael Lanfranchi, Justin F Gainor, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2014
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinibJustin F Gainor, Carol A Sherman, Kathryn Willoughby, et al.Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancerJaime L Schneider, Alona Muzikansky, Elizabeth Krueger, et al.Pageof 47